CAGE Bio Inc. is making strides in dermatological drug development with its ionic liquid formulation, CGB-500, showing promising results in clinical trials for atopic dermatitis. The company's CEO, Nitin Joshi, PhD, shared insights into the development process and the potential of this innovative treatment approach.